戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 erved Cardiac Function Heart Failure with an Aldosterone Antagonist).
2 nt with ACE inhibitor, ARB, beta blocker, or aldosterone antagonist.
3 raction were less likely to be prescribed an aldosterone antagonist.
4 s, or the addition of a thiazide diuretic or aldosterone antagonist.
5 luding ACE inhibitors, beta-blockers, and an aldosterone antagonist.
6 (ACE) inhibitors, beta-blockers, and even an aldosterone antagonist.
7 onverting-enzyme inhibitor, beta blocker, or aldosterone antagonist.
8 sin) II blockers, neprilysin inhibitors, and aldosterone antagonists.
9  angiotensin-converting enzyme inhibitors or aldosterone antagonists.
10  in ischemic events in patients treated with aldosterone antagonists.
11 l suppression with angiotensin II (AT-II) or aldosterone antagonists.
12 in-II modulation 92.8%, beta-blockers 91.5%, aldosterone antagonists 46.3%), and 71.0% had an implant
13 s 53.8%; OR, 0.63; 95% CI, 0.42-0.95), or an aldosterone antagonist (50.4% vs 53.5%; OR, 0.69; 95% CI
14 e: beta-blocker (92.2% versus 86.0%, +6.2%), aldosterone antagonist (60.3% versus 34.5%, +25.1%), car
15 ed Cardiac Function in Heart Failure With an Aldosterone Antagonist), 719 (19%) patients had AF on th
16 yme inhibitor (ACEI), beta-blocker (BB), and aldosterone antagonist (AldA) therapies for patients wit
17 erved Cardiac Function Heart Failure with an Aldosterone Antagonist)-Americas, PARAGON-HF (Prospectiv
18 erved Cardiac Function Heart Failure With an Aldosterone Antagonist] Americas), angiotensin receptor-
19 ared with sequential initiation, combination aldosterone antagonist and loop diuretics were more like
20 lose for hepatic encephalopathy, combination aldosterone antagonists and loop diuretics for ascites,
21 enzyme inhibitors, beta-adrenergic blockers, aldosterone antagonists, and digoxin.
22 ors, angiotensin II receptor antagonists and aldosterone antagonists are bringing new insights not on
23                                              Aldosterone antagonists are recommended for patients wit
24 antagonist therapy, 4087 (32.5%) received an aldosterone antagonist at discharge, and treatment incre
25 ilysin inhibitors at discharge, receiving an aldosterone antagonist at discharge, having a cardiac re
26 le patients, 1,023 (9.1%) were prescribed an aldosterone antagonist at discharge.
27 nd fewer patients in the uRDN group received aldosterone antagonists at 6 months (26 of 65 [40.0%] vs
28                          In clinical trials, aldosterone antagonists decrease cardiovascular mortalit
29 nic heart failure in more than a decade: the aldosterone antagonist eplerenone in 2003 and a fixed do
30 eta-blockers, angiotensin II inhibitors, and aldosterone antagonists followed by the beta(2)-agonist
31  symptoms, angiotensin-receptor blockers and aldosterone antagonists have additional benefits.
32 bitors, angiotensin II receptor blockers and aldosterone antagonists have all been shown to decrease
33 tensin receptor blockers, beta-blockers, and aldosterone antagonists have improved mortality in patie
34 ngiotensin receptor blockers, beta-blockers, aldosterone antagonists, hydralazine/isosorbide dinitrat
35 otensin II receptor blockers, beta-blockers, aldosterone antagonists, hydralazine/nitrates, statin th
36 locker use, evidence-based beta-blocker use, aldosterone-antagonist, hydralazine/nitrate; p < 0.05) e
37 ngiotensin receptor blockers, beta-blockers, aldosterone antagonists, implantable cardioverter defibr
38  beta-blockers in 20.3% (50.5% of eligible), aldosterone antagonists in 24.1% (87.4% of eligible), hy
39 receptor blockers (ARBs), beta blockers, and aldosterone antagonists in adults with systemic RVs.
40            Prior studies suggest underuse of aldosterone antagonists in eligible patients as well as
41 anism for the vascular protective effects of aldosterone antagonists in humans and support targeting
42  of ACE inhibitors, ARBs, beta blockers, and aldosterone antagonists in patients with systemic RVs.
43                From 2006 to 2009, the use of aldosterone antagonists increased from 6.0% to 13.4% (p
44                          Although SPIR is an aldosterone antagonist, its antitumor effects are indepe
45 erved Cardiac Function Heart Failure With an Aldosterone Antagonist; n=3445) comparing spironolactone
46 tment with ACE inhibitors, beta-blockers, an aldosterone antagonist, or their combinations.
47  not COX-2 inhibitors, with corticosteroids, aldosterone antagonists, or anticoagulants produces sign
48              Concomitant use of nsNSAIDs and aldosterone antagonists produced an IRR for UGIB of 11.0
49  angiotensin II type 1 receptor blockers, or aldosterone antagonists promote beneficial renal actions
50 erved Cardiac Function Heart Failure with an Aldosterone Antagonist randomized clinical trial, which
51                          In clinical trials, aldosterone antagonists reduce cardiovascular ischemia a
52 Angiotensin-converting enzyme inhibitors and aldosterone antagonists should also be used in these pat
53                                              Aldosterone antagonists slow the progression of chronic
54 iPro rats that did versus did not ingest the aldosterone antagonist spironolactone had lower distal n
55  found that HSP90 inhibitor geldanamycin and aldosterone antagonist spironolactone reduced DPR levels
56                                          The aldosterone antagonist spironolactone, when used in seve
57 study explored temporal trends in the use of aldosterone antagonist therapy among eligible patients w
58                                       Use of aldosterone antagonist therapy among patients with docum
59 associated with hyperkalemia was higher with aldosterone antagonist therapy at 30 days (HR, 2.54; 95%
60 as 77.6 years; of those 1070 (18.2%) started aldosterone antagonist therapy at discharge.
61                                Initiation of aldosterone antagonist therapy at hospital discharge was
62 ion >=45% from 3 large HFpEF trials (TOPCAT [Aldosterone Antagonist Therapy for Adults With Heart Fai
63                                             (Aldosterone Antagonist Therapy for Adults With Heart Fai
64                                              Aldosterone antagonist therapy for heart failure and red
65   Limited data exist regarding the impact of aldosterone antagonist therapy on cardiac structure and
66   Current guidelines recommend initiation of aldosterone antagonist therapy post-AMI for patients wit
67 opriate and potentially inappropriate use of aldosterone antagonist therapy was low and did not chang
68           Among 12,565 patients eligible for aldosterone antagonist therapy, 4087 (32.5%) received an
69 09, of whom 11,255 (13.8%) were eligible for aldosterone antagonist therapy.
70 t registry received HF guideline-recommended aldosterone antagonist therapy.
71 s of treatment with ACE inhibitors, ARBs, or aldosterone antagonists, there was no statistically sign
72 erved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) and randomized to spiron
73 atment of Preserved Cardiac Function with an Aldosterone Antagonist (TOPCAT) is an ongoing randomized
74 erved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) patients with heart fail
75 erved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial and related to the
76 erved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial before initiation
77 erved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial of 1372 patients w
78 erved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial who were in sinus
79 erved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial.
80 erved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial.
81 erved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial.
82 erved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial (TOPCAT), 3400 patients com
83 erved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial) and extracted those featur
84 erved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial) participants in the Americ
85 erved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial) suggested clinical benefit
86 erved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial)-Americas study, we examine
87 erved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial).
88 erved Cardiac Function Heart Failure with an Aldosterone Antagonist trial).
89 erved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial; n=218).
90 erved Cardiac Function Heart Failure With an Aldosterone Antagonist) trial participants (n = 379) usi
91         Spironolactone (SP), an FDA approved aldosterone antagonist, triggers the proteasomal degrada
92 s 27%), and higher rates of beta-blocker and aldosterone antagonist use (P<0.0001 for all) than those
93             There was also wide variation in aldosterone antagonist use among hospitals (0%-90.6%).
94                            Although rates of aldosterone antagonist use are increasing slightly over
95                                              Aldosterone antagonist use in eligible patients was asso
96                                              Aldosterone antagonist use varied from 0% to 40% among h
97 ted with improved 24-month survival, whereas aldosterone antagonist use was not.
98 are antihypertensive treatment starting with aldosterone antagonists was initiated under blinding to
99 erved Cardiac Function Heart Failure With an Aldosterone Antagonist) was categorized as poor, interme
100 ndependently associated with prescription of aldosterone antagonists were a history of diabetes, hear
101 bitors or angiotensin receptor blockers, and aldosterone antagonists were prescribed in 18.8%, 10.6%,

 
Page Top